Advertisement

Menopause: What Is the Role of the General Practitioner?

  • G. Tresoldi
  • Italian Society of General Practitioners
Part of the Medical Science Symposia Series book series (MSSS, volume 13)

Abstract

The complexity and the variety of problems to be managed in the climacteric period strongly suggests that one doctor act as a primary “point of reference” for the patient offering advice based on her individual history, family, and lifestyle [1–3].

Keywords

General Practitioner Endometrial Cancer Hormone Replacement Therapy Postmenopausal Hormone Therapy Postmenopausal Estrogen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Guidelines for counseling postmenopausal women about preventive hormone therapy. American College of Physicians Ann Intern Med 1992;117(12):1038–41.Google Scholar
  2. 2.
    Genazzani AR, Zichella L (editors). La terapia ormonale in climaterio o postmenopausa. Atti della 1 conferenza Nazionale di consenso in scienze ginecologoche e ostetriche, Madonna do Campiglio 17–24 marzo 1996-Churchill Livingstone.Google Scholar
  3. 3.
    “Women’s health” supplement to The Lancet. Lancet 1997;349(Suppl.):1–26.Google Scholar
  4. 4.
    Traynor V, Britt H, Sayer GP. Menopause: Its management in general practice. Aus Family Physician 1995;24:407–11.Google Scholar
  5. 5.
    O’Connor V, et al. The menopause and hormone replacement therapy: Australian general practitioners’ self-reported opinions, attitudes and behaviour. Fam Pract 1996;13:421–26.PubMedCrossRefGoogle Scholar
  6. 6.
    Hammond CB. Management of menopause. Am Fam Phys 1997;55:1667–73.Google Scholar
  7. 7.
    Beresford SA, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349:458–61.PubMedCrossRefGoogle Scholar
  8. 8.
    Colditz GA, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med 1995;332:1589–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Wise J. Hormone replacement therapy increases risk of breast cancer. BMJ 1997;315:969.Google Scholar
  10. 10.
    Sellers TA, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127:973–80.PubMedGoogle Scholar
  11. 11.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis. Lancet 1997;350:1047–43. See also commentaries pages 1042, 1043.CrossRefGoogle Scholar
  12. 12.
    Nicol-Smith L. Causality, menopause, and depression: A critical review of the literature. BMJ 1996;313:1229–32.PubMedGoogle Scholar
  13. 13.
    Hunter MS. Depression and the menopause. BMJ 1996;313:1217–18.PubMedGoogle Scholar
  14. 14.
    AHA Science Advisory. Guide to primary prevention of cardiovascular diseases. Circulation 1997;95:2329–31.Google Scholar
  15. 15.
    The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestogen regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestogen Interventions (PEPI) Trial. JAMA 1995;273:199–208.CrossRefGoogle Scholar
  16. 16.
    Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. New Engl J Med 1993;329:247–53.PubMedCrossRefGoogle Scholar
  17. 17.
    Grodstein F, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New Engl J Med 1996;335:453–61.PubMedCrossRefGoogle Scholar
  18. 18.
    Rossouw JE. Estrogens for prevention of coronary heart disease. Putting the brakes on the bandwagon. Circulation 1996;94:2982–85.PubMedGoogle Scholar
  19. 19.
    Wenger NK. Coronary heart disease: An older woman’s major health risk. BMJ 1997;315:1085–90.PubMedGoogle Scholar
  20. 20.
    Pedersen AT, et al. Hormone replacement therapy and risk of non-fatal stroke. Lancet 1997;350:1277–83.PubMedCrossRefGoogle Scholar
  21. 21.
    Consensus development statement: Who are candidates for prevention and treatment for osteoporosis? Osteoporosis Int 1997;7:1–6.Google Scholar
  22. 22.
    Schneider DL, et al. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA 1997;277:543–47 (JAMA ed. italiana vol. 9 n.6:264–70).PubMedCrossRefGoogle Scholar
  23. 23.
    Borroni M, et al. Idee guida per la prevenzione e la diagnosi di osteporosi e per la prevenzione delle fratture su base osteoporotica. Ricercae Practica 1997;13:158–67.Google Scholar
  24. 24.
    Grodstein F, Stampfer MJ, et al. Postmenopausal hormone therapy and mortality. New Engl J Med 1997;336:1769–75.PubMedCrossRefGoogle Scholar
  25. 25.
    Grady D, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37.PubMedGoogle Scholar
  26. 26.
    Ettinger B, et al. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87:6–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Crosignani PG, Paoletti R (editors). Hormone replacement and the menopause. Eur Men J 1996;3(3):195–256.Google Scholar
  28. 28.
    Guilbert JJ. Guida pedagogica. Armando editore 1981.Google Scholar

Copyright information

© Kluwer Academic Publishers and Fondazione Giovanni Lorenzini 1999

Authors and Affiliations

  • G. Tresoldi
  • Italian Society of General Practitioners

There are no affiliations available

Personalised recommendations